eLife (Aug 2019)
Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B
- Timo Vögtle,
- Sumana Sharma,
- Jun Mori,
- Zoltan Nagy,
- Daniela Semeniak,
- Cyril Scandola,
- Mitchell J Geer,
- Christopher W Smith,
- Jordan Lane,
- Scott Pollack,
- Riitta Lassila,
- Annukka Jouppila,
- Alastair J Barr,
- Derek J Ogg,
- Tina D Howard,
- Helen J McMiken,
- Juli Warwicker,
- Catherine Geh,
- Rachel Rowlinson,
- W Mark Abbott,
- Anita Eckly,
- Harald Schulze,
- Gavin J Wright,
- Alexandra Mazharian,
- Klaus Fütterer,
- Sundaresan Rajesh,
- Michael R Douglas,
- Yotis A Senis
Affiliations
- Timo Vögtle
- ORCiD
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Sumana Sharma
- ORCiD
- Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
- Jun Mori
- ORCiD
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Zoltan Nagy
- ORCiD
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Daniela Semeniak
- Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany
- Cyril Scandola
- Université de Strasbourg, Institut National de la Santé et de la Recherche Médicale, Etablissement Français du Sang Grand Est, Unité Mixte de Recherche-S 1255, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France
- Mitchell J Geer
- ORCiD
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Christopher W Smith
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Jordan Lane
- Sygnature Discovery Limited, Nottingham, United Kingdom
- Scott Pollack
- ORCiD
- Sygnature Discovery Limited, Nottingham, United Kingdom
- Riitta Lassila
- ORCiD
- Coagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, University of Helsinki, Helsinki University Hospital, Helsinki, Finland; Aplagon Oy, Helsinki, Finland
- Annukka Jouppila
- Coagulation Disorders Unit, Helsinki University Hospital Research Institute, Helsinki, Finland
- Alastair J Barr
- ORCiD
- Department of Biomedical Science, Faculty of Science & Technology, University of Westminster, London, United Kingdom
- Derek J Ogg
- ORCiD
- Peak Proteins Limited, Alderley Park, Cheshire, United Kingdom
- Tina D Howard
- Peak Proteins Limited, Alderley Park, Cheshire, United Kingdom
- Helen J McMiken
- Peak Proteins Limited, Alderley Park, Cheshire, United Kingdom
- Juli Warwicker
- Peak Proteins Limited, Alderley Park, Cheshire, United Kingdom
- Catherine Geh
- Peak Proteins Limited, Alderley Park, Cheshire, United Kingdom
- Rachel Rowlinson
- Peak Proteins Limited, Alderley Park, Cheshire, United Kingdom
- W Mark Abbott
- Peak Proteins Limited, Alderley Park, Cheshire, United Kingdom
- Anita Eckly
- Université de Strasbourg, Institut National de la Santé et de la Recherche Médicale, Etablissement Français du Sang Grand Est, Unité Mixte de Recherche-S 1255, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France
- Harald Schulze
- ORCiD
- Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany
- Gavin J Wright
- ORCiD
- Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
- Alexandra Mazharian
- ORCiD
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Klaus Fütterer
- ORCiD
- School of Biosciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham, United Kingdom
- Sundaresan Rajesh
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Michael R Douglas
- Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Neurology, Dudley Group NHS Foundation Trust, Dudley, United Kingdom; School of Life and Health Sciences, Aston University, Birmingham, United Kingdom
- Yotis A Senis
- ORCiD
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Université de Strasbourg, Institut National de la Santé et de la Recherche Médicale, Etablissement Français du Sang Grand Est, Unité Mixte de Recherche-S 1255, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France
- DOI
- https://doi.org/10.7554/eLife.46840
- Journal volume & issue
-
Vol. 8
Abstract
The immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor G6b-B is critical for platelet production and activation. Loss of G6b-B results in severe macrothrombocytopenia, myelofibrosis and aberrant platelet function in mice and humans. Using a combination of immunohistochemistry, affinity chromatography and proteomics, we identified the extracellular matrix heparan sulfate (HS) proteoglycan perlecan as a G6b-B binding partner. Subsequent in vitro biochemical studies and a cell-based genetic screen demonstrated that the interaction is specifically mediated by the HS chains of perlecan. Biophysical analysis revealed that heparin forms a high-affinity complex with G6b-B and mediates dimerization. Using platelets from humans and genetically modified mice, we demonstrate that binding of G6b-B to HS and multivalent heparin inhibits platelet and megakaryocyte function by inducing downstream signaling via the tyrosine phosphatases Shp1 and Shp2. Our findings provide novel insights into how G6b-B is regulated and contribute to our understanding of the interaction of megakaryocytes and platelets with glycans.
Keywords